130 related articles for article (PubMed ID: 18696119)
1. Effects of pegylated interferon alpha-2a on hepatitis-C-virus-associated glomerulonephritis.
Sugiura T; Yamada T; Kimpara Y; Fujita N; Goto K; Koyama N
Pediatr Nephrol; 2009 Jan; 24(1):199-202. PubMed ID: 18696119
[TBL] [Abstract][Full Text] [Related]
2. Rapidly deteriorating renal function with membranoproliferative glomerulonephritis Type 1 associated with hepatitis C treated successfully with steroids and antiviral therapy: a case report and review of literature.
Ahmed MS; Wong CF; Shawki H; Kapoor N; Pandya BK
Clin Nephrol; 2008 Apr; 69(4):298-301. PubMed ID: 18397706
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of HCV-related cryoglobulinemic glomerulonephritis with double-filtration plasmapheresis and interferon combination therapy.
Namba T; Shiba R; Yamamoto T; Hirai Y; Moriwaki T; Matsuda J; Kadoya H; Takeji M; Yamada Y; Yoshihara H; Yamauchi A
Clin Exp Nephrol; 2010 Aug; 14(4):372-6. PubMed ID: 20467773
[TBL] [Abstract][Full Text] [Related]
4. Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN.
Alric L; Plaisier E; Thébault S; Péron JM; Rostaing L; Pourrat J; Ronco P; Piette JC; Cacoub P
Am J Kidney Dis; 2004 Apr; 43(4):617-23. PubMed ID: 15042538
[TBL] [Abstract][Full Text] [Related]
5. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.
Yamada G; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
Clin Drug Investig; 2008; 28(1):9-16. PubMed ID: 18081356
[TBL] [Abstract][Full Text] [Related]
6. Multicenter study of pegylated interferon α-2a monotherapy for hepatitis C virus-infected patients on hemodialysis: REACH study.
Kikuchi K; Akiba T; Nitta K; Masakane I; Ando R; Izumi N; Atsukawa M; Yamazaki C; Kato F; Hotta N; Tominaga Y; Orito E; Hora K; Nagasawa M; Kasahara H; Kawaguchi M; Kimura H; Ikebe N; Kawanishi H; Moriishi M; Shigemoto K; Harada T; Hirakata H; Watanabe H; Nosaki T; Tsubouchi H; Imawari M; Akizawa T
Ther Apher Dial; 2014 Dec; 18(6):603-11. PubMed ID: 25196061
[TBL] [Abstract][Full Text] [Related]
7. Progressive renal failure and blindness due to retinal hemorrhage after interferon therapy for hepatitis C virus-associated membranoproliferative glomerulonephritis.
Suzuki T; Yonemura K; Miyaji T; Suzuki H; Takahira R; Fujigaki Y; Fujimoto T; Hishida A
Intern Med; 2001 Aug; 40(8):708-12. PubMed ID: 11518107
[TBL] [Abstract][Full Text] [Related]
8. Antiviral therapy of symptomatic HCV-mixed cryoglobulinemia after liver transplant: case report and literature review.
Francesca Donato M; Banfi G; Cresseri D; Battista Fogazzi G; Martin P; Messa P; Fabrizi F
Int J Artif Organs; 2013 May; 36(5):367-72. PubMed ID: 23446762
[TBL] [Abstract][Full Text] [Related]
9. Mutations in the interferon sensitivity-determining region of hepatitis C virus genotype 2a correlate with response to pegylated-interferon-alpha 2a monotherapy.
Hayashi K; Katano Y; Honda T; Ishigami M; Itoh A; Hirooka Y; Nakano I; Urano F; Yoshioka K; Toyoda H; Kumada T; Goto H
J Med Virol; 2009 Mar; 81(3):459-66. PubMed ID: 19152412
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of pegylated interferon alpha-2a therapy for chronic hepatitis C in HIV-infected patients with haemophilia.
Zhang RF; Sun HQ; Huang Q; Wang JR; Zhang XX; Liu XN; Ma Q; Lu HZ
Haemophilia; 2010 May; 16(3):502-7. PubMed ID: 20028427
[TBL] [Abstract][Full Text] [Related]
11. The IL28B effect on hepatitis C virus kinetics among HIV patients after the first weeks of pegylated-interferon/ribavirin treatment varies according to hepatitis C virus-1 subtype.
Rivero-Juarez A; Lopez-Cortes LF; Camacho A; Caruz A; Torres-Cornejo A; Martinez-Dueñas L; Ruiz-Valderas R; Torre-Cisneros J; Gutierrez-Valencia A; Rivero A
AIDS; 2013 Jul; 27(12):1941-7. PubMed ID: 23917425
[TBL] [Abstract][Full Text] [Related]
12. Rapid virological response tailors the duration of treatment in hepatitis C virus genotype 3 patients treated with pegylated interferon alfa-2a and ribavirin in Pakistan.
Gill U; Aziz H; Gill ML
Int J Infect Dis; 2013 Nov; 17(11):e1017-21. PubMed ID: 23896656
[TBL] [Abstract][Full Text] [Related]
13. Renal manifestations of hepatitis C virus infection. Extrahepatic complications often are silent--and thus overlooked.
Bandi L
Postgrad Med; 2003 Feb; 113(2):73-6, 86. PubMed ID: 12611116
[TBL] [Abstract][Full Text] [Related]
14. Therapy with interferon-alpha plus ribavirin for membranoproliferative glomerulonephritis induced by hepatitis C virus.
Lopes EP; Valente LM; Silva AE; Kirsztajn GM; Cruz CN; Ferraz ML
Braz J Infect Dis; 2003 Oct; 7(5):353-7. PubMed ID: 14552746
[TBL] [Abstract][Full Text] [Related]
15. Effect of combination therapy (ribavirin and interferon) in HCV-related glomerulopathy.
Sabry AA; Sobh MA; Sheaashaa HA; Kudesia G; Wild G; Fox S; Wagner BE; Irving WL; Grabowska A; El-Nahas AM
Nephrol Dial Transplant; 2002 Nov; 17(11):1924-30. PubMed ID: 12401848
[TBL] [Abstract][Full Text] [Related]
16. Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: impact of bilharziasis and fibrosis stage.
Derbala MF; Al Kaabi SR; El Dweik NZ; Pasic F; Butt MT; Yakoob R; Al-Marri A; Amer AM; Morad N; Bener A
World J Gastroenterol; 2006 Sep; 12(35):5692-8. PubMed ID: 17007024
[TBL] [Abstract][Full Text] [Related]
17. Renal disease in hepatitis C-positive liver transplant recipients.
Kendrick EA; McVicar JP; Kowdley KV; Bronner MP; Emond MJ; Alpers CE; Gretch DR; Carithers RL; Perkins JD; Davis CL
Transplantation; 1997 May; 63(9):1287-93. PubMed ID: 9158023
[TBL] [Abstract][Full Text] [Related]
18. Pegylated interferon for recurrent hepatitis C in liver transplant recipients with renal failure: a prospective cohort study.
Mukherjee S; Gilroy RK; McCashland TM; Schafer DF
Transplant Proc; 2003 Jun; 35(4):1478-9. PubMed ID: 12826198
[TBL] [Abstract][Full Text] [Related]
19. Early and sustained virological response in non-responders with chronic hepatitis C: a randomized open-label study of pegylated interferon-alpha-2a versus pegylated interferon-alpha-2b.
Scotto G; Fazio V; Fornabaio C; Tartaglia A; Di Tullio R; Saracino A; Angarano G
Drugs; 2008; 68(6):791-801. PubMed ID: 18416586
[TBL] [Abstract][Full Text] [Related]
20. Long-term follow up of sustained viral response after treatment of hepatitis C with pegylated interferon alpha-2a in hemodialysis patients.
Dzekova P; Asani A; Selim G; Gelev S; Trajceska L; Amitov V; Selja N; Zabzun M; Mena S; Gaseva M; Sikole A
Int J Artif Organs; 2009 Mar; 32(3):180-4. PubMed ID: 19440994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
